Modern Veterinary Medicine for the Treatment of Joint Disease and Lameness
Equine lameness is the number one reason for vet call-outs and is often difficult to manage, especially in the longer term. This can lead to frequent re-treatments and, increased supplement and drug intake. Arthramid® Vet treats the underlying causes of joint lameness in animals, including both early and late stages of osteoarthritis (OA).
Arthramid® Vet is a synthetic 2.5% cross-linked polyacrylamide hydrogel for intra-articular injection. It is clinically proven to be fully biocompatible, non-pyrogenic and neuro-innocuous.
Arthramid® Vet hydrogel acts as a dynamic tissue scaffold that integrates into the joint itself, reducing pain and providing long-term shock absorption that restores the joint to healthy function.
Conference - News
Location: TSB Arena, Queens Wharf WGT NZ – NZVA Conference In The Capital
May 22nd – 24th, 2019
Dr Leigh DeClifford “Use of 2.5% PAAG in managing joint pain”
Location: Great Lakes Regional Conference – National Association of Education Procurement.
September 26th, 2019 – 2:45pm to 3:40pm
Dr Florent David, “Is it worth considering a 2.5% PAAG as a first intention joint therapy”
Arthramid® Vet (AV) is produced by a patented technology called In-line Cross-Linking Technology (ILX Technology), forcing water molecules between the cross-linked polymers of polyacrylamide (CAS No. 9003-05-8), that provides the gel with exceptional molecular stability and the ability to retain its viscoelastic properties in situ.
The hydrogel becomes incorporated into the joint capsule and surrounding tissues by a combination of cell migration and vessel ingrowth. Vessel in-growth begins immediately after gel injection with host macrophages entering the gel, which is unable to engulf the polymer.
Macrophages are gradually replaced by fibroblasts and endothelial cells, which in time develop into a thin vessel-bearing fibrous network inside the gel. Integration and invasion of synovial cells in the gel is seen by day 14 with a sub-synovial layer traversed by thin strands of connective tissue and vessels covered by a new and hyper-cellular synovial lining facing the joint cavity formed by day 30 and at up to 2 years
Every detail is taken care of
“Our philosophy of innovation remains at the centre of everything we do. Our core mission is to improve the health, performance, and wellbeing of equine patients through technological innovation, intensive R & D and global partner alliances in the veterinary industry leading to better patient outcomes and client enjoyment of the animals we love.”
Achieving the best outcomes
2 Year old Thoroughbred in full race training: Dream was a 2-year-old Thoroughbred in full race training that started to resent being ridden and...
12 Year old Mixed Breed Gelding: Pluto was a 12-year-old mixed breed gelding that had been used for Hunting for over six years and developed...
Innovative Medical Solutions
Arthramid Vet White Paper
Get your copy of our 24 page white paper covering Treatment of Joint Lameness, Pathophysiology, Manufacturing, Mechanism of Action, Clinical Safety and Putting it into Practice.
Send Me The White Paper
Read More on Case Selection Criteria
Understanding the complexity of disease processes associated with joint pain remains a constant dilemma in clinical practice and as with any disease process, an accurate diagnosis is essential.
Arthritis describes inflammation of a joint and can occur after single or repetitive episodes of trauma. The term incorporates synovitis, capsulitis, sprain, intra-articular fractures, meniscal tears, and osteoarthritis(OA).
These pathological conditions are ‘a group of overlapping distinct diseases which may have different aetiologies, but with similar biologic, morphologic, and clinical outcomes.
Although conventional concepts of OA emphasise the direct and predominant involvement of cartilage and bone in OA development, it is increasingly recognised that the synovium also contributes to the central pathophysiological event of cartilage matrix depletion.
Cases suitable for treatment with Arthramid®Vet are those in which lameness is localised to the joint by clinical examination, intra-articular analgesia, radiography, ultrasound, MRI, CT and/or Scintigraphy. Conditions that respond to treatment with Arthramid®Vet include acute and chronic synovitis, capsulitis, meniscal tears, OA, and subchondral bone cysts. It is essential that anamnesis of data of ongoing infection, concomitant medication, surgery or potential fracture is reviewed prior to injection to prevent possible infections or use of the product for conditions other than for which it is indicated.
Read More on Case Management Protocols
Animals should be rested for 48 hours immediately after treatment. After this time the animal can return to exercise compared to its level of comfort.
Clinical studies show that tissue integration and subsequent augmentation of the joint capsule takes between 2 and 4 weeks to occur, although a response to treatment can be seen earlier than that in some cases.
Animals typically show a gradual reduction in lameness during the first week after treatment and a concurrent reduction in reaction to passive flexion. This continues to improve over the ensuing 2 to 3 weeks. By 4 weeks no further improvement is expected. Re-examination at 4 weeks is therefore indicated to either administer a second dose – in those that have only partially responded- or to reassess accuracy of the diagnosis.
It is important for owners to understand the time lag for a treatment effect to be seen as this contrasts with conventional therapies. In this respect and due to its long lasting effect it may also be prudent to consider treating the animal during periods of reduced exercise demands or early on in the animals training programme.
Mode Of Action
Not All Hydrogels Are The Same
PAAG products, although often considered equal, have clear differences in composition, manufacturing and injection techniques as well as their ability to interact with surrounding tissues. Characteristics that determine the safety and effectiveness of each hydrogel.
Upon injection into joints, the Arthramid® Vet, a uniquely cross-linked 2.5% polyacrylamide hydrogel, adheres to the synovial lining through its ability to exchange water molecules. The ensuing influx of mononuclear cells reduces exposure of synoviocytes to pro-inflammatory cytokines in the inflamed or diseased joint. The gel becomes progressively integrated into the synovial lining and its immediate surrounding tissue of the inner joint capsule by a combination of cell migration and vessel ingrowth forming a thick, cushion-like membrane, over 14 to 28 days, consisting of vessel integrated gel covered by a new and hypercellular synovial cell lining.
Arthramid®Vet, therefore, has an augmentation effect on the joint capsule and synovium, increasing elasticity and tensile strength and improving its capacity to transfer load. This augmentation and cushioning causes a subsequent reduction in mechanoreceptor and nociceptor activation in the capsule itself. In turn, this further reduces synovitis and its successively deleterious effects as a result.
Unlike other hydrogels, Arthramid®Vet becomes fully integrated into the surrounding tissue (rather than encapsulated) and is therefore long-lasting. Arthramid®Vet does not elicit a foreign body reaction or harbour infection.
Comments From Clinical Practice
I have been using Arthramid Vet for 4 years treating TB’s, SB’s and equestrian horses. 90% of my work is lameness identification and treatment. I have injected over 600 joints with Arthramid Vet and have experienced no side effects. I have used all of the alternative joint treatments over the last 50 years and consider Arthramid Vet (in conjunction with triamcinolone in an overall treatment strategy) superior to all other treatments. 85% of my TB lameness localises to the intercarpal joint. (read more)
I was one of the first vets to use Arthramid worldwide and have now used Arthramid for over 10 years in our clinic. We have injected over a thousand horses and have found it to be very safe. It has been a major game-changer in the way we treat OA in our patients. We have fantastic results with really frustrating cases and are still working on new indications and treatment schemes for the product. We are also looking into the ongoing research, especially around the Mode of Action. (read more)
Get In Touch
32 Hill Road, Cambridge, NZ
Phone +64 (09) 8013 253
Arthramid Vet New Zealand
Registered in New Zealand to: Innovative Medical Solutions Limited NZBN: 9429041325544, 32 Hill Road, Cambridge 3494, New Zealand. Registered pursuant to the ACVM Act 1997 Number A11596. See www.foodsafety.govt.nz for registration conditions.